Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Alkermes Plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Alkermes Plc - Product Pipeline Review - 2014', provides an overview of the Alkermes Plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alkermes Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alkermes Plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alkermes Plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alkermes Plc's pipeline products Reasons to buy - Evaluate Alkermes Plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alkermes Plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alkermes Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alkermes Plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alkermes Plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Alkermes Plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Alkermes Plc Snapshot 5 Alkermes Plc Overview 5 Key Information 5 Key Facts 5 Alkermes Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Alkermes Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Alkermes Plc - Pipeline Products Glance 13 Alkermes Plc - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Alkermes Plc - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Alkermes Plc - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Alkermes Plc - Drug Profiles 18 aripiprazole lauroxil 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 (samidorphan + buprenorphine hydrochloride) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 (samidorphan + olanzapine) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ALKS-7106 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ALKS-8700 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 samidorphan 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 (methylsamidorphan + opioid analgesic) 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 olanzapine ER 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 RDB-1419 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Alkermes Plc - Pipeline Analysis 30 Alkermes Plc - Pipeline Products by Target 30 Alkermes Plc - Pipeline Products by Route of Administration 31 Alkermes Plc - Pipeline Products by Molecule Type 32 Alkermes Plc - Pipeline Products by Mechanism of Action 33 Alkermes Plc - Recent Pipeline Updates 34 Alkermes Plc - Dormant Projects 41 Alkermes Plc - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 insulin human 42 r-hFSH 42 samidorphan 42 teriparatide 42 Alkermes Plc - Company Statement 43 Alkermes Plc - Locations And Subsidiaries 46 Head Office 46 Other Locations & Subsidiaries 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Alkermes Plc, Key Information 5 Alkermes Plc, Key Facts 5 Alkermes Plc - Pipeline by Indication, 2014 7 Alkermes Plc - Pipeline by Stage of Development, 2014 8 Alkermes Plc - Monotherapy Products in Pipeline, 2014 9 Alkermes Plc - Combination Treatment Modalities in Pipeline, 2014 10 Alkermes Plc - Partnered Products in Pipeline, 2014 11 Alkermes Plc - Partnered Products/ Combination Treatment Modalities, 2014 12 Alkermes Plc - Pre-Registration, 2014 13 Alkermes Plc - Phase III, 2014 14 Alkermes Plc - Phase II, 2014 15 Alkermes Plc - Phase I, 2014 16 Alkermes Plc - Preclinical, 2014 17 Alkermes Plc - Pipeline by Target, 2014 30 Alkermes Plc - Pipeline by Route of Administration, 2014 31 Alkermes Plc - Pipeline by Molecule Type, 2014 32 Alkermes Plc - Pipeline Products by Mechanism of Action, 2014 33 Alkermes Plc - Recent Pipeline Updates, 2014 34 Alkermes Plc - Dormant Developmental Projects,2014 41 Alkermes Plc - Discontinued Pipeline Products, 2014 42 Alkermes Plc, Other Locations 46 Alkermes Plc, Subsidiaries 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.